IP
Ines Pires da Silva
Champalimaud Foundation, The University of Sydney, Universidade Nova de Lisboa Faculdade de Ciências Médicas, Melanoma Institute Australia
Research areas: Medicine · Oncology · Cancer Immunotherapy and Biomarkers · Cutaneous Melanoma Detection and Management · Melanoma and MAPK Pathways
0000-0003-3540-8906
Employment
-
Champalimaud Foundation Medical Oncologist2025 - Present
-
University of Sydney Senior Lecturer2021 - Present
-
Blacktown & Mount Druitt Hospital Oncologist2021 - 2024
-
Melanoma Institute Australia Clinical and research Melanoma Fellow2016 - Present
Education
-
Universidade Nova de Lisboa Faculdade de Ciências Médicas PhD2011 - 2016
-
Universidade Nova de Lisboa Faculdade de Ciências Médicas Medical Doctor1999 - 2005
Projects & Funding
-
NeoPlatform: Neoadjuvant translational research platform to predict, monitor and enhance response to immunotherapy. NHMRC2025 - 2030
-
Neoadjuvant research platform to personalize therapy for melanoma patients. MRA2025 - 2028
-
Liver metastases: a niche of resistance and of therapeutic opportunities for all cancers. NHMRC2023 - 2025
-
Matching optimal drug therapy to overcome organ-specific resistance to standard immunotherapy in melanoma CINSW2022 - 2024
-
Clinical models predictive of response and survival in advanced melanoma patients treated with anti-PD1 monotherapy or in combination with anti-CTLA-4 Oncology Spring Meeting2021 - Present
-
Risk factors of immune-checkpoint inhibitors mediated liver, gastrointestinal, endocrine and skin toxicity (ICEMELT). WSLHD and its Research and Education Network2021 - 2022
-
Patterns and management of progression on 1st line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients. Conquer Cancer2021 - Present
-
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. Conquer Cancer, supported by Friends and Family of Dr. and Mrs. Ronald Beller2020 - Present
-
Effective therapies for patients with high risk in-transit disease. Melanoma Research Alliance2020 - Present
-
Improving survival in melanoma by matching optimal drug therapy for individual patients. Tour de Cure2020 - Present
-
Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. Conquer Cancer Foundation2019 - Present
-
Study of the association of the imunomodulatory effect of the dual HER2 blockade and clinical response to these drugs in the context of HER2+ Advanced Breast Cancer Instituto Português de Oncologia de Lisboa2016 - Present
-
Evaluation of clinical and immunological outcomes of the association of anti-CTLA-4 with radiotherapy and/or steroids. Oncology Spring Meeting2015 - Present
-
Identification of a novel pathogenic germline KDR variant in melanoma. 3rd Portuguese Melanoma Symposium2015 - Present
Publications (97)
- Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Save
- The soluble HLA repertoire captures neoantigenic, cryptic, and tumour-associated peptides in melanoma Save
- Immunotherapy for early-stage cutaneous squamous cell carcinoma Save
- Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study Save
- Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients Save
- Data from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Supplementary Figure S1 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Supplementary Figure S2 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Supplementary Table S1 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Supplementary Table S2 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Supplementary Table S3 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Supplementary Table S4 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure Save
- Long‐Term Outcomes and Toxicities in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens Save
- Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs Save
- Predicting the likelihood of elevated transaminases in lung cancer patients undergoing immune checkpoint blockade Save
- Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies Save
- A meta-analysis of VEGF inhibitor efficacy in patients with liver metastases across cancer types. Save
- Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save
- Supplementary Figure S1 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy Save